CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
Maravai LifeSciences (NASDAQ: MRVI) has released its 2024 Sustainability Report, highlighting significant progress across four key areas: Product Innovation, People, Governance, and Sustainable Growth. The company launched 49 new products and completed a state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold. Notable achievements include establishing an RNA Innovation Center with Johns Hopkins University and manufacturing over 130 GMP batches for mRNA.
The company demonstrated strong employee engagement with a 95% participation rate in their annual survey and expanded their employee resource programs. In governance, they appointed R. Andrew Eckert as independent Chairman and strengthened their intellectual property position. Sustainability initiatives included enhanced greenhouse gas emissions reporting and renewable energy projects, with their Leland facility's solar panels generating over 180,000 kWh.
Maravai LifeSciences (NASDAQ: MRVI) ha pubblicato il suo Rapporto di Sostenibilità 2024, evidenziando importanti progressi in quattro aree chiave: Innovazione di Prodotto, Persone, Governance e Crescita Sostenibile. L'azienda ha lanciato 49 nuovi prodotti e completato una struttura GMP all'avanguardia a San Diego, aumentando di dieci volte la capacità di produzione di mRNA. Tra i risultati rilevanti si annovera la creazione di un Centro di Innovazione RNA con la Johns Hopkins University e la produzione di oltre 130 lotti GMP per mRNA.
La società ha mostrato un forte coinvolgimento dei dipendenti con un tasso di partecipazione del 95% al sondaggio annuale e ha ampliato i programmi di risorse per i dipendenti. In ambito governance, è stato nominato R. Andrew Eckert come Presidente indipendente e rafforzata la posizione sulla proprietà intellettuale. Le iniziative di sostenibilità hanno incluso un miglioramento nella rendicontazione delle emissioni di gas serra e progetti di energia rinnovabile, con i pannelli solari dell'impianto di Leland che hanno prodotto oltre 180.000 kWh.
Maravai LifeSciences (NASDAQ: MRVI) ha publicado su Informe de Sostenibilidad 2024, destacando avances significativos en cuatro áreas clave: Innovación de Producto, Personas, Gobernanza y Crecimiento Sostenible. La compañía lanzó 49 nuevos productos y completó una instalación GMP de última generación en San Diego, aumentando la capacidad de producción de ARNm diez veces. Entre los logros destacados se encuentra el establecimiento de un Centro de Innovación en ARN con la Universidad Johns Hopkins y la fabricación de más de 130 lotes GMP de ARNm.
La empresa demostró un fuerte compromiso de los empleados con una tasa de participación del 95% en su encuesta anual y amplió sus programas de recursos para empleados. En gobernanza, nombraron a R. Andrew Eckert como presidente independiente y fortalecieron su posición en propiedad intelectual. Las iniciativas de sostenibilidad incluyeron una mejora en la reporte de emisiones de gases de efecto invernadero y proyectos de energía renovable, con los paneles solares de su planta en Leland generando más de 180,000 kWh.
Maravai LifeSciences (NASDAQ: MRVI)는 2024년 지속 가능성 보고서를 발표하며 제품 혁신, 인재, 거버넌스, 지속 가능한 성장 등 네 가지 핵심 분야에서 중요한 진전을 강조했습니다. 회사는 49개의 신제품을 출시하고 샌디에이고에 최첨단 GMP 시설을 완공하여 mRNA 생산 능력을 10배로 늘렸습니다. 주요 성과로는 Johns Hopkins University와 함께 RNA 혁신 센터를 설립하고 130개 이상의 GMP 배치를 생산한 것이 포함됩니다.
직원 참여도는 연례 설문조사에서 95% 참여율을 기록하며 강한 참여를 보였고, 직원 자원 프로그램도 확대했습니다. 거버넌스 측면에서는 R. Andrew Eckert를 독립 이사회 의장으로 임명하고 지적 재산권 입지를 강화했습니다. 지속 가능성 이니셔티브로는 온실가스 배출 보고 강화와 재생 에너지 프로젝트가 포함되었으며, Leland 시설의 태양광 패널은 180,000kWh 이상을 생산했습니다.
Maravai LifeSciences (NASDAQ : MRVI) a publié son rapport de durabilité 2024, mettant en lumière des progrès significatifs dans quatre domaines clés : innovation produit, personnel, gouvernance et croissance durable. L'entreprise a lancé 49 nouveaux produits et achevé une installation GMP ultramoderne à San Diego, multipliant par dix la capacité de production d'ARNm. Parmi les réalisations notables, on compte la création d'un centre d'innovation ARN avec l'université Johns Hopkins et la fabrication de plus de 130 lots GMP d'ARNm.
L'entreprise a démontré un fort engagement des employés avec un taux de participation de 95 % à leur enquête annuelle et a élargi ses programmes de ressources pour les employés. En matière de gouvernance, R. Andrew Eckert a été nommé président indépendant et la position en propriété intellectuelle a été renforcée. Les initiatives de durabilité ont inclus un renforcement du reporting des émissions de gaz à effet de serre et des projets d'énergie renouvelable, avec les panneaux solaires de leur site de Leland produisant plus de 180 000 kWh.
Maravai LifeSciences (NASDAQ: MRVI) hat seinen Nachhaltigkeitsbericht 2024 veröffentlicht und dabei bedeutende Fortschritte in vier Schlüsselbereichen hervorgehoben: Produktinnovation, Mitarbeiter, Governance und nachhaltiges Wachstum. Das Unternehmen brachte 49 neue Produkte auf den Markt und errichtete eine hochmoderne GMP-Anlage in San Diego, wodurch die mRNA-Produktionskapazität verzehnfacht wurde. Zu den bemerkenswerten Erfolgen zählt die Einrichtung eines RNA-Innovationszentrums in Zusammenarbeit mit der Johns Hopkins University sowie die Herstellung von über 130 GMP-Chargen für mRNA.
Das Unternehmen zeigte eine starke Mitarbeiterbindung mit einer 95%igen Teilnahmequote an der jährlichen Umfrage und erweiterte seine Mitarbeiterressourcenprogramme. Im Bereich Governance wurde R. Andrew Eckert zum unabhängigen Vorsitzenden ernannt und die Position im Bereich geistiges Eigentum gestärkt. Nachhaltigkeitsinitiativen umfassten verbesserte Berichterstattung über Treibhausgasemissionen und Projekte im Bereich erneuerbare Energien, wobei die Solaranlagen der Leland-Anlage über 180.000 kWh erzeugten.
- Launched 49 new products including CleanCap® M6 analog at GMP quality
- Completed new GMP facility increasing mRNA production capacity by 10x
- Manufactured over 130 GMP batches for mRNA
- Strengthened intellectual property with additional CleanCap® patents in China and Canada
- High employee engagement with 95% participation rate in annual survey
- None.
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth
Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives
Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program
SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of “Maravai LifeSciencesReleases 2024 Sustainability Report”. The corrected title is “Maravai LifeSciences Releases 2024 Sustainability Report”.
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2024 Sustainability Report, available on the Company’s Sustainability webpage (investors.maravai.com/sustainability). The new report highlights progress during calendar year 2024 across Maravai’s four priority areas – Product Innovation, Our People, Governance, and Sustainable Growth – and underscores the Company’s commitment to sustainable value creation.
“By embedding sustainability into every facet of our operations—from employee engagement to GMP scaleup — we foster innovation, strengthen our business resilience, and create long-term value for all stakeholders,” said Trey Martin, Chief Executive Officer. “Our 2024 achievements position Maravai to remain our customers’ first choice as they advance their programs in next-generation therapeutics and diagnostics.”
Key highlights from the 2024 report include:
Product Innovation
- Launched 49 new products across portfolio brands, including CleanCap® M6 analog now available at GMP quality
- Completed state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold
- Established RNA Innovation Center in collaboration with Johns Hopkins University
- Added to our GMP manufacturing expertise and have now manufactured over 130 GMP batches for mRNA
Our People
- Achieved
95% participation rate in our annual employee engagement survey, receiving over 2,600 comments - Expanded WE (We are Empowered) Employee Resource Group to facilitate advocacy, mentorship, and outreach across the organization
- Implemented new career framework creating transparent progression paths for all employees
- Continued our Impact Day program throughout 2024, with employees contributing approximately 800 volunteer hours
Governance
- Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman of the Board
- Adopted formal, publicly available Human Rights Policy
100% of standing Board Committees chaired by independent members- Strengthened intellectual property position with additional CleanCap® patents in China and Canada
Sustainable Growth
- Enhanced greenhouse gas emissions data collection and expanded Scope 3 emissions reporting
- Leland, North Carolina facility's solar panels generated over 180,000 kWh, offsetting approximately
20% of facility's energy use - San Diego EV charging stations helped save over 19,000 gallons of gasoline
- Advanced planning for lab plastics recycling program and single-use plastic phase-out
The 2024 report was prepared in reference to the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB) and Greenhouse Gas Protocol frameworks and maps selected disclosures to relevant U.N. Sustainable Development Goals (SDGs).
About Maravai
Maravai LifeSciences is an innovative lifesciences company that provides critical products to enable the development of breakthrough therapeutics, vaccines, cell and gene therapies and diagnostics. Through its TriLink BioTechnologies, Glen Research, Alphazyme and Cygnus Technologies brands, Maravai delivers complex nucleic acid chemistries, differentiated mRNA and enzyme solutions, and gold standard biologics safety tests to a global customer base spanning large pharmaceutical companies, emerging biotechs and leading academic institutions.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements related to future product offerings, facility capabilities, and sustainability initiatives. Forward-looking statements are neither historical facts nor assurances of future performance and are subject to risks and uncertainties that could cause actual results to differ materially. A detailed discussion of these risks is included in Maravai’s most recent Annual Report on Form 10K and subsequent filings with the U.S. Securities and Exchange Commission. Maravai undertakes no obligation to update forward-looking statements except as required by law.
Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@maravai.com
FAQ
What major achievements did Maravai LifeSciences (MRVI) report in its 2024 Sustainability Report?
How did Maravai LifeSciences (MRVI) expand its manufacturing capacity in 2024?
What sustainability initiatives did Maravai LifeSciences (MRVI) implement in 2024?
Who was appointed as the new Chairman of Maravai LifeSciences (MRVI) in 2024?
What employee engagement metrics did Maravai LifeSciences (MRVI) achieve in 2024?
